IDEXX Labs (NASDAQ: IDXX) reported Q1 EPS of $1.01, $0.08 better than the analyst estimate of $0.93. Revenue for the quarter came in at $537.66 million versus the consensus estimate of $524.93 million.

• Reports revenue growth of 16% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 17% reported and 13% organic
• Achieves record-setting first quarter 2,822 premium instrument placements, representing 21% year-over-year growth
• Delivers EPS of $1.01, driven by high revenue growth, strong operating margin gains and net benefits from U.S. Tax Reform
• Maintains 2018 reported revenue guidance of $2,205 million - $2,245 million, reflecting reported growth of 12% - 14%, and raises 2018 organic revenue growth guidance by 1% to 10.5% - 12.5%, which is offset by change in foreign exchange rate outlook
• Increases 2018 EPS outlook range by $0.02 to $4.06 - $4.20, as operational upsides are offset by impacts from updated foreign exchange rate outlook

GUIDANCE:

IDEXX Labs sees FY2018 EPS of $4.06-$4.20, versus the consensus of $4.12. IDEXX Labs sees FY2018 revenue of $2.205-2.245 billion, versus the consensus of $2.22 billion.

For earnings history and earnings-related data on IDEXX Labs (IDXX) click here.